Twitter sentiment analysis from Iran about COVID 19 vaccine

来自伊朗的推特用户对新冠疫苗的情绪分析

阅读:1

Abstract

BACKGROUND AND AIMS: The development of vaccines against COVID-19 has been a global purpose since the World Health Organization declared the pandemic. People usually use social media, especially Twitter, to transfer knowledge and beliefs on global concerns like COVID-19-vaccination, hence, Twitter is a good source for investigating public opinions. The present study aimed to assess Persian tweets to (1) analyze Iranian people's view toward COVID-19 vaccination. (2) Compare Iranian views toward a homegrown and imported COVID-19-vaccines. METHODS: First, a total of 803278 Persian tweets were retrieved from Twitter, mentioning COVIran Barekat (the homegrown vaccine), Pfizer/BioNTech, AstraZeneca/Oxford, Moderna, and Sinopharm (imported vaccines) between April 1, 2021 and September 30, 2021. Then, we identified sentiments of retrieved tweets using a deep learning sentiment analysis model based on CNN-LSTM architecture. Finally, we investigated Iranian views toward COVID-19-vaccination. RESULTS: (1) We found a subtle difference in the number of positive sentiments toward the homegrown and foreign vaccines, and the latter had the dominant positive polarity. (2) The negative sentiment regarding homegrown and imported vaccines seems to be increasing in some months. (3) We also observed no significant differences between the percentage of overall positive and negative opinions toward vaccination amongst Iranian people. CONCLUSIONS: It is worrisome that the negative sentiment toward homegrown and imported vaccines increases in Iran in some months. Since public healthcare agencies aim to increase the uptake of COVID-19 vaccines to end the pandemic, they can focus on social media such as Twitter to promote positive messaging and decrease opposing views.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。